Cladribine
- Generic Name
- Cladribine
- Brand Names
- Litak, Mavenclad
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClN5O3
- CAS Number
- 4291-63-8
- Unique Ingredient Identifier
- 47M74X9YT5
- Background
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
- Indication
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)
CLARITY Extension Study
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2020-12-07
- Target Recruit Count
- 867
- Registration Number
- NCT00641537
- Locations
- 🇬🇧
Research Site, Stoke-on-Trent, United Kingdom
🇷🇺Reseach Site, Saratov, Russian Federation
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT00483067
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2020-10-12
- Target Recruit Count
- 172
- Registration Number
- NCT00436826
- Locations
- 🇪🇸
Research Site, Seville, Spain
🇪🇸Research site, Barcelona, Spain
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- Conditions
- Hairy Cell LeukemiaRecurrent Hairy Cell Leukemia
- Interventions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT00412594
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2005-11-24
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 18
- Registration Number
- NCT00258271
- Locations
- 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2014-02-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 1326
- Registration Number
- NCT00213135
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
- Conditions
- Lymphoma, Lymphoblastic
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00199017
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath
- Conditions
- Lymphoma, LymphoblasticAdult Acute Lymphocytic Leukemia T-cell
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 8
- Registration Number
- NCT00199030
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
- Conditions
- Adult Acute Lymphocytic Leukemia
- Interventions
- Procedure: CNS irradiationProcedure: Mediastinal IrradiationProcedure: Stem cell transplantation (SCT)
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1883
- Registration Number
- NCT00198991
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
- Conditions
- Leukemia, Myelocytic, Acute
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- University Hospital, Bonn
- Target Recruit Count
- 50
- Registration Number
- NCT00126321
- Locations
- 🇩🇪
Medical Clinic & Policlinic III, University Bonn, Bonn, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.